title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Conclusion | ’ cooperative behavior, ’ | To conclude, we provide novel evidence showing that individuals’ cooperative decisions toward their opponents vary depending on outcome-based feedback of their prior competition. Negative feedback (defeat) compared to positive feedback (victory) had a negative effect on the subsequent cooperative behavior toward oppone... | PMC10073108 | |
Materials and methods | PMC10073108 | |||
Participants | This experiment was performed in the Experimental Laboratory at the Department of Psychology, University of Nanjing. To ensure adequate power in the current research, we performed a power analysis using R to determine the sample size of our study with a mixed three-way ANOVA design. We calculated that to maintain 80% p... | PMC10073108 | ||
Procedure | PMC10073108 | |||
Pre-competition measures | We administered several questionnaires with the aim of controlling for potential individual differences and how they might relate to task performance | PMC10073108 | ||
Competition with outcome feedback manipulation | We used a between-participants design to manipulate outcome feedback. Participants were randomly assigned to receive one of four types of outcome feedback (victory vs. defeat vs. uncertain competitive outcome vs. no competition (control)). We used a standard version of the Deese–Roediger–McDermott (DRM) paradigmTo stim... | PMC10073108 | ||
Risky cooperation: two-person Public Goods Game | After completing the competition stage, participants played a one-shot, two-player public goods game (PGG). This provides the simplest environment to assess how participants behaved toward their opponents within the context of risky cooperation. At the start of the PGG, participants were informed of their endowment (10... | PMC10073108 | ||
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-32523-6. | PMC10073108 | ||
Acknowledgements | CORTEX | This work was supported by STI2030-Major Projects (2022ZD0205104 to Y.L.) and the Project of Philosophy and Social Science Research in Colleges and Universities of Jiangsu Province (2020SJA0017 to Y.L.). This research has benefited from the financial support of IDEXLYON from Université de Lyon (project INDEPTH) within ... | PMC10073108 | |
Author contributions | Y.L. and J-C. D. conceived the study. Y.L. and Z.L. designed the study; Z.L. collected the data. Z.L. and Y.W. analyzed the data under the supervision of Y.L. Y.L. wrote the draft. E.D., F.M., and J-C.D. edited the draft. | PMC10073108 | ||
Data availability | The raw datasets containing a codebook are available at | PMC10073108 | ||
Competing interests | The authors declare no competing interests. | PMC10073108 | ||
References | PMC10073108 | |||
Background | hemorrhage, abortion | HYPERTENSIVE DISORDER, HEMORRHAGE, OBSTETRIC COMPLICATION, COMPLICATION | Unlike other causes such as abortion, obstetric complications like hemorrhage, and hypertensive disorders of pregnancy, which are difficult to resolve for women who give birth out of health facilities are persisted or increased to be the cause of maternal mortality in Ethiopia. Direct obstetric complications resulted i... | PMC10006562 |
Method | A community-based cross-sectional study was conducted to assess the baseline information as a part of a randomized control trial study. The sample size that was calculated for the cohort study with the assumptions to detect an increase in a minimum acceptable diet from 11 to 31%, with 95% CIs and 80% power, an intra-cl... | PMC10006562 | ||
Result | headache | VAGINAL BLEEDING, COMPLICATIONS | The prevalence of self-reported pregnancy-related complications and home delivery were 79(15.9%, CI; 12.7–19.1) and 46.90% (95%CI; 42.5–51.1) respectively. Women who did not face vaginal bleeding were five times AOR 5.28(95% CI: 1.79–15.56) more like to give birth at home than those who faced this problem. Women who di... | PMC10006562 |
Conclusion | vaginal bleeding, headache | VAGINAL BLEEDING, COMPLICATIONS | This study concluded that home delivery was high among the study participants whereas pregnancy-related complications such as vaginal bleeding and severe headache were identified as protective factors for facility delivery. Hence, the researchers recommended the incorporation of “storytelling” into the existing health ... | PMC10006562 |
Keywords | PMC10006562 | |||
Background | death, thrive, hemorrhage, labor/uterine rupture, abortion | HYPERTENSIVE DISORDER, HEMORRHAGE, OBSTETRIC COMPLICATION, COMPLICATIONS | Relating to maternal health, the recent focus of the global health agenda has expanded beyond the survival of women and their babies to ensuring they thrive and achieve their full potential for health and well-being [In less developed countries, maternal health intervention targets mostly women who can have complicatio... | PMC10006562 |
Method | PMC10006562 | |||
Study setting and period | Chekorsa | The study was conducted in two districts of Jimma Zone named, Dedo districts and Seka Chekorsa districts in Oromia region, Southwest Ethiopia. The districts have 36 Kebeles each with a total population of 237,844 in Dedo district and 296,440 in Seka Chekorsa district in 2013 E.C (Ethiopian calendar). Based on the 2013 ... | PMC10006562 | |
Study design | A community-based cross-sectional study design was employed to collect the data. | PMC10006562 | ||
Study population | All pregnant women who were selected from the selected kebeles in the Dedo district and Seka Chokorsa district kebeles and who fulfil the inclusion criteria were the study population. | PMC10006562 | ||
Inclusion and exclusion criteria | hyperemesis, congenital abnormality | COMPLICATIONS | The women were included based on the inclusion criteria set for the cohort study which includes pregnant women in the third trimester who have lived in the selected kebeles for not less than six months, and were willing to be visited by data collectors and supervisors after the child delivery. Similarly, exclusion crit... | PMC10006562 |
Sample size determination and sampling procedure | COMPLICATIONS | Sample size that was calculated for the cohort study was used for this study. It was determined with the assumptions to detect an increase in a minimum acceptable diet from 11 to 31% [The cohort study was proposed on any pregnant women residing in the selected kebeles who fulfill the inclusion criteria. During the anal... | PMC10006562 | |
Participant Recruitment | The study areas were clustered by kebele. All third-trimester pregnant women residing in the selected kebeles were identified and enrolled in the study using the updated Health Extension Workers’ antenatal care logbook. Pregnant women were also identified through the one-to-five network to reduce the possibility of mis... | PMC10006562 | ||
Data collection tool, method, and personnel | The data collection tool was prepared from relevant literature [ | PMC10006562 | ||
Data analysis | REGRESSION | Statistical analysis was done using SPSS version 22. Descriptive statistics were used to summarize the characteristics of the participants. Bivariate logistic regression analysis was done for each variable with the outcome variable to select candidate variables at | PMC10006562 | |
Result | PMC10006562 | |||
Socio-demographic characteristics of the participants | All study participants were married and living with their partners. The mean age of the respondents was 26.78 (SD ± 4.88) years (Table
Distribution of Socio-demographic characteristics of participants | PMC10006562 | ||
Obstetric and maternal health service-related characteristics of the participants | bleeding, headache | BLEEDING, COMPLICATION, COMPLICATIONS | The mean duration of the last child delivery for which the history was asked was 36.54(SD ± 13.44) months (Table
Distribution of obstetric history of women who participated in the studyAbout 15% 79(15.9%) of women had faced pregnancy-related complications during the pregnancy of their most recently delivered child (Fi... | PMC10006562 |
Place of delivery | The majority of the women who participated in the study had given birth to their most recent delivery at home (Fig.
Distribution of place of child delivery among women who participated in the study | PMC10006562 | ||
Relationship between complication experience during pregnancy and place of delivery | COMPLICATIONS | A large number of women who faced pregnancy-related complications during their most recent pregnancy had gave birth at home (Table
Self-reported pregnancy-related complications and place of delivery among women who participated in the study | PMC10006562 | |
The logistic regression analysis result | vaginal bleeding, headache, vomiting, face/hand swelling | REGRESSION, VAGINAL BLEEDING, COMPLICATIONS | In bivariate logistic regression, vaginal bleeding, severe headache, persistent vomiting, face/hand swelling, and others were identified as candidate variables for multivariate analysis from the seven pregnancy-related complications. Two pregnancy-related complications; vaginal bleeding with a
Logistic regression anal... | PMC10006562 |
Discussion | COMPLICATIONS | This study established an association between pregnancy-related complications and place of delivery among women who had at least oneThe prevalence of self-reported pregnancyHowever, this self-reported pregnancyIn our study, home delivery among the study participants was 46.90%( 95% CI; 42.5–51.1). This result is lower ... | PMC10006562 | |
Association of pregnancy-related complications and place of child delivery | headache | VAGINAL BLEEDING, PREGNANCY COMPLICATIONS, COMPLICATION, REGRESSION, COMPLICATIONS | The logistic regression analysis result of this study identified that two of the self-reported pregnancyThe majority of the previously conducted study in Ethiopia regarding identifying factors associated with place of delivery focused on maternalThe result indicated that women who did not face vaginal bleeding were fiv... | PMC10006562 |
Conclusion and recommendation | vaginal bleeding, headache | VAGINAL BLEEDING, COMPLICATION, COMPLICATIONS | This study concluded that home delivery is high among the study participants whereas the happening of pregnancy-related complications such as vaginal bleeding and severe headache were identified as protective factors for facility delivery. Hence, the researchers recommended the incorporation of “storytelling” in awaren... | PMC10006562 |
Acknowledgements | Our special gratitude goes to Jimma University for funding this work, and to the health extension workers of the two districts for their unreserved support in participant identification. | PMC10006562 | ||
Authors’ contributions | All authors contributed to the work equally. The author(s) read and approved the final manuscript. | PMC10006562 | ||
Funding | Jimma University funded this work. | PMC10006562 | ||
Availability of data and materials | all data used to prepare this article is available within the article. If further is needed, the interested person can contact the corresponding author via bekelut23@gmail.com or bekelutybh21@gmail.com on a reasonable base. | PMC10006562 | ||
Declarations | PMC10006562 | |||
Ethics approval and consent to participate | The study protocol was reviewed and approved by Jimma University Institutional Review Board. Ethical clearance was obtained with JUIH/IRB/110/22 reference number. All methods were carried out in accordance with relevant guidelines and regulations of the university’s Institutional Review Board. All the study participant... | PMC10006562 | ||
Competing interests | not applicable.the authors declare we have no conflict of interest. | PMC10006562 | ||
References | PMC10006562 | |||
Objective: | CERVICAL LESIONS | To assess the feasibility of incorporating technology as a new alternative for treating topics on cervical lesions. | PMC10388842 | |
Method: | This is a randomized, double-blind, controlled clinical trial with a prospective design. During the realization of this study, 43 women were included and divided between groups A (ointment without silver nanoparticles n = 23) and B (ointment with silver nanoparticles n = 20) clinically healthy and who used the unified ... | PMC10388842 | ||
Results: | ADVERSE REACTION | There were no significant differences when comparing before and after the use of ointment for IVA test (p = 0.15), Schiller test (p = 0.15), cellular changes (p = 0.47) and microbiological analysis (p = 0.89) through cytology. After use, no adverse reaction was observed in the sample studied. | PMC10388842 | |
Conclusion: | ADVERSE EVENTS, CERVICAL LESIONS | Based on the results identified in this study, identified that the product is safe and does not promote adverse events. Regarding the effectiveness of the product in uterine cervical lesions, it is necessary to continue the study in phase II. Registro de Ensaios Clínicos Brasileiros: UTN: U1111-1218-2820. | PMC10388842 | |
RESUMO | PMC10388842 | |||
Objetivo: | Avaliar a viabilidade da incorporação da tecnologia como uma nova alternativa para o tratamento de lesões cervicais. | PMC10388842 | ||
Método: | Trata-se de um ensaio clínico randomizado, duplo-cego e controlado com um desenho prospectivo. Durante a realização deste estudo, foram incluídas 43 mulheres, divididas entre os grupos A (pomada sem nanopartículas de prata n = 23) e B (pomada com nanopartículas de prata n = 20), clinicamente saudáveis e usuárias do sis... | PMC10388842 | ||
Resultados: | Não houve diferenças significativas na comparação entre antes e depois do uso da pomada para o teste IVA (p = 0,15), teste de Schiller (p = 0,15), alterações celulares (p = 0,47) e análise microbiológica (p = 0,89) por meio de citologia. Após o uso, não foi observada nenhuma reação adversa na amostra estudada. | PMC10388842 | ||
Conclusões: | Com base nos resultados identificados neste estudo, identificou-se que o produto é seguro e não promove eventos adversos. Com relação à eficácia do produto em lesões cervicais uterinas, é necessária a continuidade do estudo na fase II. Registro de Ensaios Clínicos Brasileiros: UTN: U1111-1218-2820. | PMC10388842 | ||
RESUMEN | PMC10388842 | |||
Objetivo: | evaluar la viabilidad de la incorporación de la tecnología como una nueva alternativa para el tratamiento de temas sobre lesiones cervicales. | PMC10388842 | ||
Método: | DEL | Se trata de un ensayo clínico aleatorizado, doble ciego, controlado y con un diseño prospectivo. Durante la realización de este estudio se incluyeron 43 mujeres divididas entre los grupos A (pomada sin nanopartículas de plata n = 23) y B (pomada con nanopartículas de plata n = 20) clínicamente sanas y usuarias del sist... | PMC10388842 | |
Resultados: | DEL | No hubo diferencias significativas al comparar antes y después del uso de la pomada para la prueba de IVA (p = 0,15), la prueba de Schiller (p = 0,15), los cambios celulares (p = 0,47) y el análisis microbiológico (p = 0,89) mediante citología. Tras el uso, no se observó ninguna reacción adversa en la muestra estudiada... | PMC10388842 | |
Conclusiones: | DEL | Con base en los resultados identificados en este estudio, se identificó que el producto es seguro y no promueve eventos adversos. Con relación a la eficacia del producto en lesiones cervicales uterinas, es necesario continuar el estudio en fase II. Registro de Estudios Clínicos Brasileños: UTN: U1111-1218-2820. | PMC10388842 | |
DESCRIPTORS | PMC10388842 | |||
DESCRITORES | PMC10388842 | |||
DESCRIPTORES | PMC10388842 | |||
INTRODUCTION | cancer, traumatic | CANCER | Intraepithelial lesions of the cervix are localized and identifiable lesions that have a high risk of developing cancer that can be treated and eradicated when previously identifiedThere are no reports in care protocols including the administration of drugs for oral or topical use, but there are clinical exams with pos... | PMC10388842 |
METHODS | PMC10388842 | |||
Study Design and Research Participants | CERVICAL LESIONS | We carried out a prospective, randomized, double-blind, phase 1, experimental trial, including 43 women assisted by the project’s researchers. This study is a pilot investigation to examine the feasibility of a new topical treatment alternative for cervical lesions with silver nanoparticles and | PMC10388842 | |
Ointment Preparation | HPV infections | PCT, HPV INFECTION | The preparation of the ointment followed the methodology described in the patent entitled “Pharmaceutical composition for the treatment of HPV infections using barbatimão extracts” number US 9,023,405 B2, granted in the United States via an application for Patent Cooperation Treaty (PCT) and by the inventors Luiz Carlo... | PMC10388842 |
Follow-Up During the Use of the Ointment | bleeding, itching, protectors, pain, vaginal dryness | UTERINE CERVIX, ADVERSE EFFECTS, BLEEDING, ADVERSE EVENTS | The patients were monitored daily from the beginning of the use of the ointment through telephone calls guided by structured questions about possible adverse effects or difficulties in use. In addition, the patients underwent weekly consultations for assessment of the uterine cervix and safety of use. Upon return, all ... | PMC10388842 |
Data Collect | tumors | TUMORS | Data were collected between 2018 and 2020. We used visual methods to identify possible changes in the cervix such as the Visual Inspection with Acetic Acid test, Schiller test, and cervical digital photography, oncotic cytology in liquid medium and analysis of the vaginal microbiota. All exams and tests were performed ... | PMC10388842 |
Ethics Aspects | RESOLUTION | The research followed all the recommendations of Resolution nº. 466/2012 of the National Health Council (CNS) and was approved by the National Research Ethics Committee - CONEP - in 2017, under the number 2.114.908 (CAAE: 58185116.6.0000.5013). To start the assessments, the patients were previously approached for resea... | PMC10388842 | |
Statistical Analysis | We estimated that a sample size would ensure 80% power using a two-sided type I error rate of 0.05. The calculation using electronic calculator available at | PMC10388842 | ||
RESULTS | inflammation, malignancy, Lactobacillus sp., atrophy | INFLAMMATION, ATROPHY | Regarding sociodemographic characteristics, the average age of the participants was 40.2 years old. Regarding ethnicity, 60.5% (n = 26) declared to be brown and 34.9% (n = 15) white. We can also observe that 37.2% (n = 16) reported being married, 25.6% (n = 11) single and 20.9% (n = 9) in a common-law marriage. When ob... | PMC10388842 |
Results of the Pap smear in liquid medium before and after using the ointment with/without silver nanoparticles – Arapiraca, AL, Brazil, 2018. | Lactobacillus sp. | GARDNERELLA | When independently analyzing the groups with and without silver nanoparticles in the results of the Pap smear, we observed that there were no statistically significant differences in the distribution of benign reactive or reparative cell changes between the groups before (xThrough the culture of vaginal secretion, we o... | PMC10388842 |
Comparison between Pap smear before and after the use of the ointment with/without silver nanoparticles – Arapiraca, AL, Brazil, 2018. | PMC10388842 | |||
Independent statistical analysis and dependent on the results of the vaginal secretion culture between the groups with or without silver nanoparticles before and after the use of gynecological ointment – Arapiraca, AL, Brazil, 2018. | PMC10388842 | |||
DISCUSSION | inflammation | INFLAMMATION | This study evaluated the safety of Barbatimão gynecological ointment, comparing one group with and one without silver nanoparticles in a healthy cervix. To release an herbal medicine for use and sale, it needs some phases such as phase I, performed with groups of 20 to 100 healthy individualsThe main results obtained i... | PMC10388842 |
CONCLUSIONS | injuries | DISEASE, ADVERSE EFFECTS, CERVICAL CANCER | The results of this study conclude that the Barbatimão gynecological ointment with and without silver nanoparticles does not have a risk to human health since no adverse effects were observed or harmful to human health. The ointment tested here has anti-inflammatory activity, proven through the result of oncotic cytolo... | PMC10388842 |
REFERENCES | PMC10388842 | |||
Background | LUNG | Low-dose spiral computed tomography (LDCT) may not lead to a clear treatment path when small to intermediate-sized lung nodules are identified. We have combined flow cytometry and machine learning to develop a sputum-based test (CyPath Lung) that can assist physicians in decision-making in such cases. | PMC9862555 | |
Methods | lung cancer, cancer from non-cancer | LUNG CANCER | Single cell suspensions prepared from induced sputum samples collected over three consecutive days were labeled with a viability dye to exclude dead cells, antibodies to distinguish cell types, and a porphyrin to label cancer-associated cells. The labeled cell suspension was run on a flow cytometer and the data collect... | PMC9862555 |
Results | DISEASE | Automated analysis combined with machine learning resulted in a predictive model that achieved an area under the ROC curve (AUC) of 0.89 (95% CI 0.83–0.89). The sensitivity and specificity were 82% and 88%, respectively, and the negative and positive predictive values 96% and 61%, respectively. Importantly, the test wa... | PMC9862555 | |
Supplementary Information | The online version contains supplementary material available at 10.1186/s12931-023-02327-3. | PMC9862555 | ||
Keywords | PMC9862555 | |||
Background | lung cancer, leukemias from non-neoplastic cytopenias | LUNG CANCER | Early detection of lung cancer through screening can increase survival and reduce morbidity [Efforts are underway to develop non-invasive tests that can be used after LDCT to improve screening’s predictive value [Automated FCM techniques have been combined with machine learning approaches to distinguish leukemias from ... | PMC9862555 |
Methods | PMC9862555 | |||
Collection sites | Participants were identified and enrolled at a physician’s or study coordinator’s office at one of the following sites: Atlantic Health System, NJ; Mt. Sinai Hospital, NY; Radiology Associates of Albuquerque, NM; South Texas Veterans Healthcare System, TX; and Waterbury Pulmonary Associates, CT. Each site had received ... | PMC9862555 | ||
Participant information | angina, obstructive lung disease, non-cancer, cancer, emphysema, lung cancer, cough, asthma, COPD | OBSTRUCTIVE LUNG DISEASE, CANCER, CHRONIC BRONCHITIS, EMPHYSEMA, LUNG CANCER, COPD, ASTHMA | Participants (males and females) were enrolled in one of two groups. The non-cancer group included participants (aged 52–79) who were either current smokers with a smoking history of at least 20 pack-years, or current non-smokers with a smoking history of at least 20 pack-years, who quit smoking within the past 15 year... | PMC9862555 |
Sample collection | non-cancer, cancer | ADVERSE EVENTS, CANCER, DISEASE | Sample donors were trained on how to use the acapella assist device (Smiths Medical, St. Paul, MN), and expel their sample by coughing into a specimen cup, repeating this procedure at home for three consecutive days and storing their specimen cup in a refrigerator. Sample donors did not report experiencing any adverse ... | PMC9862555 |
Sample size considerations | cancer, cancer / non-cancer | CANCER | Enrolment for the LSRII data set continued until sufficient cancer samples were collected to build a robust model for automated analysis. For test development and model training, we needed enough cancer samples in order to create subsets of samples through repeated randomization that would allow us to evaluate cancer p... | PMC9862555 |
Sputum processing | Sputum was dissociated and labeled using recently published protocols [A small aliquot of cells was set aside for use as controls while the majority was divided into two tubes for the main analysis. Both tubes were labeled with Fixable Viability Stain 510 (FVS510) and CD45-PE. One tube, the “blood tube”, received CD66b... | PMC9862555 | ||
Flow cytometry | Sputum samples were acquired on a BD LSRII flow cytometer (BD Biosciences) equipped with four lasers (405 nm, 488 nm, 561 nm, and 633 nm) or on a Navios EX (Beckman Coulter Life Sciences) equipped with three lasers (405 nm, 488 nm and 638 nm). The settings used on each flow cytometer had been previously shown to genera... | PMC9862555 | ||
Results | PMC9862555 | |||
Automated flow cytometric selection of viable single cells | Heuristics-guided | EVENT, LUNG, EVENTS, BSE | The first stage of the CyPath Lung assay is the automated FCM identification of viable single cells (Fig. Automated gating of FCM data. Each sample run included polystyrene beads of known diameter (5–30 µm NIST beads), compensation tubes for each fluorochrome channel used, unstained sputum, and an antibody isotype sput... | PMC9862555 |
Development of the CyPath Lung cancer/non-cancer classifier | non-cancer, cancer, cancer or non-cancer | REGRESSION, CANCER, EVENTS, LUNG | The second stage of the CyPath Lung assay is the analysis of light scatter and fluorescence signals from the viable single cells identified in the first stage by automated FCM. Logistic regression models describe a relationship between predictor variables and a categorical (in our case binary cancer/non-cancer) respons... | PMC9862555 |
Running the CyPath Lung assay pipeline | cancer, anomalies | CANCER, LUNG | Having developed the two stages of the CyPath Lung assay, we could now assemble the full pipeline, including quality control steps, determination of predictive variable values, and classification of samples (Fig. CyPath Lung data processing pipeline. The schematic represents the following main elements: QC measures (to... | PMC9862555 |
Discussion | lung cancer, cancer, tumor, cancer from non-cancer | TUMOR, LUNG, CANCER, THORACIC, LUNG CANCER | To our knowledge, this study is the first that combines automated flow cytometric analysis with machine learning to predict the presence of lung cancer from sputum samples. Sputum as diagnostic material provides a snapshot of the tumor itself, of its microenvironment (ME), and of its field of cancerization (FoC). Exper... | PMC9862555 |
Conclusion | lung cancer, lung cancer carcinogenesis | LUNG CANCER, LUNG | CyPath Lung is a non-invasive, sputum-based test for the early diagnosis of lung cancer. It uses a flow cytometric platform to analyze the cellular content of sputum with the analysis being fully automated and thus unbiased. The test is robust to differences in sample handling and processing and captures important pred... | PMC9862555 |
Acknowledgements | -20 | We would like to thank all sputum donors for their participation in this study and David Rodriguez for his assistance with figure preparations. Flow cytometric data acquisition was performed at the University of Texas Health San Antonio flow cytometry core facility (LSRII), which is supported by NIH-NCI P30 CA054174-20... | PMC9862555 | |
Author contributions | RS, SAH | MEL: Conceptualization; data curation; formal analysis; code development/testing; visualization; writing—original draft; writing—review and editing. XTR: Data curation; project administration; writing—review and editing. JR, LHB, PRA, JRS, MG, S-CL: Formal analysis; investigation; methodology; writing—review and editin... | PMC9862555 | |
Funding | This research was funded by bioAffinity Technologies. | PMC9862555 | ||
Availability of data and materials | Flow cytometry data files to reproduce the figures can be found in the FLOW repository ( | PMC9862555 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.